447 related articles for article (PubMed ID: 36377339)
1. Immune checkpoint inhibitor gastritis is often associated with concomitant enterocolitis, which impacts the clinical course.
Haryal A; Townsend MJ; Baskaran V; Srivoleti P; Giobbie-Hurder A; Sack JS; Isidro RA; LeBoeuf NR; Buchbinder EI; Hodi FS; Grover S
Cancer; 2023 Feb; 129(3):367-375. PubMed ID: 36377339
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of appendectomy as a potential risk factor for immune checkpoint inhibitor-associated enterocolitis.
Krasnow NA; Chute DF; Falade AS; North CM; Reynolds KL; Dougan ML
Immunotherapy; 2023 Aug; 15(12):913-920. PubMed ID: 37292001
[TBL] [Abstract][Full Text] [Related]
3. Concurrent immune checkpoint inhibition and selective immunosuppressive therapy in patients with immune-related enterocolitis.
Badran YR; Zou F; Durbin SM; Dutra BE; Abu-Sbeih H; Thomas AS; Altan M; Thompson JA; Qiao W; Leet DE; Lai PY; Horick NK; Postow MA; Faleck DM; Wang Y; Dougan M
J Immunother Cancer; 2023 Jun; 11(6):. PubMed ID: 37349130
[TBL] [Abstract][Full Text] [Related]
4. Mucosal inflammation predicts response to systemic steroids in immune checkpoint inhibitor colitis.
Mooradian MJ; Wang DY; Coromilas A; Lumish M; Chen T; Giobbie-Hurder A; Johnson DB; Sullivan RJ; Dougan M
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32414860
[TBL] [Abstract][Full Text] [Related]
5. Gastrointestinal mucosal toxicities from immune checkpoint inhibitors: Current understanding and future directions.
Dougan M
Immunol Rev; 2023 Sep; 318(1):11-21. PubMed ID: 37455375
[TBL] [Abstract][Full Text] [Related]
6. Immune Checkpoint Inhibitor-associated Diarrhea and Colitis: A Systematic Review and Meta-analysis of Observational Studies.
Tran AN; Wang M; Hundt M; Chugh R; Ohm J; Grimshaw A; Ciarleglio M; Hung KW; Proctor DD; Price CC; Laine L; Al-Bawardy B
J Immunother; 2021 Oct; 44(8):325-334. PubMed ID: 34380976
[TBL] [Abstract][Full Text] [Related]
7. Management of Patients With Immune Checkpoint Inhibitor-Induced Enterocolitis: A Systematic Review.
Collins M; Soularue E; Marthey L; Carbonnel F
Clin Gastroenterol Hepatol; 2020 May; 18(6):1393-1403.e1. PubMed ID: 32007539
[TBL] [Abstract][Full Text] [Related]
8. Characteristics and outcomes of cancer patients with pre-existing microscopic colitis after exposure to PD-1 and PD-L1 inhibitors.
Thomas AR; Liu C; Tong YT; Tan D; Altan M; Siddiqui BA; Shatila M; Khan A; Thomas AS; Wang Y
J Cancer Res Clin Oncol; 2023 Jul; 149(8):5429-5436. PubMed ID: 36451045
[TBL] [Abstract][Full Text] [Related]
9. Characteristics of Immune Checkpoint Inhibitor-Induced Colitis: A Systematic Review.
Nakane T; Mitsuyama K; Yamauchi R; Kakuma T; Torimura T
Kurume Med J; 2023 Jul; 68(2):43-52. PubMed ID: 37100606
[TBL] [Abstract][Full Text] [Related]
10. Incidence of immune checkpoint inhibitor-mediated diarrhea and colitis (imDC) in patients with cancer and preexisting inflammatory bowel disease: a propensity score-matched retrospective study.
Sleiman J; Wei W; Shah R; Faisal MS; Philpott J; Funchain P
J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34158318
[TBL] [Abstract][Full Text] [Related]
11. Colitis following the use of immune checkpoint inhibitors: A real-world analysis of spontaneous reports submitted to the FDA adverse event reporting system.
Hu Y; Gong J; Zhang L; Li X; Li X; Zhao B; Hai X
Int Immunopharmacol; 2020 Jul; 84():106601. PubMed ID: 32422528
[TBL] [Abstract][Full Text] [Related]
12. Evolution and recurrence of gastrointestinal immune-related adverse events induced by immune checkpoint inhibitors.
de Malet A; Antoni G; Collins M; Soularue E; Marthey L; Vaysse T; Coutzac C; Chaput N; Mateus C; Robert C; Carbonnel F
Eur J Cancer; 2019 Jan; 106():106-114. PubMed ID: 30476730
[TBL] [Abstract][Full Text] [Related]
13. P067 Immune Checkpoint Inhibitor Colitis in a Community-Based Hospital System.
Rampersad A; Abrams G; Bauer C
Am J Gastroenterol; 2021 Dec; 116(Suppl 1):S17-S18. PubMed ID: 37461984
[TBL] [Abstract][Full Text] [Related]
14. Pancreatitis and Hyperlipasemia in the Setting of Immune Checkpoint Inhibitor Therapy.
Townsend MJ; Liu M; Giobbie-Hurder A; Sack JS; LeBoeuf NR; Hodi FS; McNabb-Baltar J; Grover S
J Natl Compr Canc Netw; 2023 Aug; 21(8):831-840.e3. PubMed ID: 37549912
[TBL] [Abstract][Full Text] [Related]
15. Tofacitinib and faecal microbiota transplantation in treating checkpoint inhibitor-induced enterocolitis: case report.
Holmstroem RB; Dahl EK; Helms M; Nielsen HV; Andersen JB; Bjerrum JT; Svane IM; Ellebaek E; Seidelin JB
BMJ Open Gastroenterol; 2022 Dec; 9(1):. PubMed ID: 36581371
[TBL] [Abstract][Full Text] [Related]
16. Characteristics of Immune Checkpoint Inhibitor-Associated Gastritis: Report from a Major Tertiary Care Center.
Farha N; Faisal MS; Allende DS; Sleiman J; Shah R; Farha N; Funchain P; Philpott JR
Oncologist; 2023 Aug; 28(8):706-713. PubMed ID: 36905577
[TBL] [Abstract][Full Text] [Related]
17. Impact of antibiotic therapy on the development and response to treatment of immune checkpoint inhibitor-mediated diarrhea and colitis.
Abu-Sbeih H; Herrera LN; Tang T; Altan M; Chaftari AP; Okhuysen PC; Jenq RR; Wang Y
J Immunother Cancer; 2019 Sep; 7(1):242. PubMed ID: 31488205
[TBL] [Abstract][Full Text] [Related]
18. Immune-related adverse events in a patient with eosinophilic enteritis treated with immune checkpoint inhibitors (anti-PD-1).
Cybulska-Stopa B; Kamińska-Winciorek G; Dyduch G
Melanoma Res; 2020 Dec; 30(6):619-624. PubMed ID: 32809991
[TBL] [Abstract][Full Text] [Related]
19. Characteristics, treatment, and outcome of patients with bowel perforation after immune checkpoint inhibitor exposure.
Pizuorno Machado A; Shatila M; Liu C; Lu Y; Altan M; Glitza Oliva IC; Zhao D; Zhang HC; Thomas A; Wang Y
J Cancer Res Clin Oncol; 2023 Aug; 149(9):5989-5998. PubMed ID: 36611109
[TBL] [Abstract][Full Text] [Related]
20. Impact of Selective Immunosuppressive Therapy on Subsequent Immune-Related Adverse Events After Immune Checkpoint Inhibitor-Induced Colitis Treatment.
Pizuorno Machado A; Shatila M; Glitza Oliva IC; Altan M; Siddiqui B; Zhou Y; Varatharajalu K; Zhang HC; Thomas A; Wang Y
Am J Clin Oncol; 2023 Aug; 46(8):360-365. PubMed ID: 37219360
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
